Kristin Bedard, PhD, is a founding scientist and chief scientific officer of Kineta Immuno-Oncology. Kristin's work on RIG-I biology and novel small-molecule drug approaches has led to three highly regarded funding grants with the National Institutes of Health (NIH) and four government contracts for infectious disease and oncology indications totaling more than $35 million. She is the co-inventor on 15 filed US patent applications for novel classes of immune agonists and corresponding methods of identification. She serves as director-at-large for the Healthcare Businesswomen's Association in Seattle and is chairwoman of a Drug Discovery Scientific Review Committee for the NIH Small Business Section.
Kristin has built the discovery research programs since 2009 at Kineta Inc., which encompasses a diverse pipeline of therapeutic and vaccine adjuvant candidates. Under her direction, Kineta established the AViiD™ platform for identifying novel innate immune modulators, including small-molecule RIG-I agonists. Additionally, her team has progressed the antiviral drug LHF-535 toward clinical development for the pandemic threat Lassa hemorrhagic fever.
Kristin received her undergraduate degrees in Microbiology and Biochemistry at Pennsylvania State University and earned a PhD degree in Molecular Virology from the University of California - Irvine. She completed a postdoctoral fellowship at the Fred Hutchinson Cancer Research Center studying viral-induced skin and cervical cancers. Her focus on small-molecule immune modulators is instrumental in shifting the paradigm in immuno-oncology drug development strategies.